1-(3-Methyl-1-methylene-butyl)-pyrrolidine | 152794-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(3-Methyl-1-methylene-butyl)-pyrrolidine
• 英文别名: 1-(4-Methylpent-1-en-2-yl)pyrrolidine
• CAS: 152794-99-5
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: FSNAKXREBZPBIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  四氢吡咯 、 4-甲基-2-戊酮 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 反应 24.0h， 生成 1-(3-Methyl-1-methylene-butyl)-pyrrolidine 、 1-((Z)-1,3-Dimethyl-but-1-enyl)-pyrrolidine
  参考文献：
  名称：

  Stereoselective synthesis of the bicyclo[5.3.0]decane portion of the diterpene antibiotic guanacastepene using a pyrylium-ylide [5+2] cycloaddition reaction

  摘要：

  Treatment of 14 with Ac2O/Et3N resulted in [5+2] cyclization to give 2, which was further elaborated into 20, thus establishing the required stereochemistry in the top-half of guanacastepene 1. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)00851-6

文献信息

• 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
  申请人：Vollrath Benedikt

  公开号：US20120270866A1

  公开（公告）日：2012-10-25

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.

  本文提供了PAK抑制剂以及利用PAK抑制剂治疗中枢神经系统疾病，如神经精神障碍的方法。
• PAK INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Afraxis, Inc.

  公开号：US20130158043A1

  公开（公告）日：2013-06-20

  Provided herein are methods of utilizing PAK inhibitors for the treatment of cancer. Further provided herein are compounds and formulations utilized for the treatment of cancer.

  本文提供了利用PAK抑制剂治疗癌症的方法。此外，还提供了用于治疗癌症的化合物和配方。
• Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
  申请人：CTXT PTY LTD

  公开号：US10005792B2

  公开（公告）日：2018-06-26

  A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(═O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式（1a）、（1b）或（1c）化合物 其中：n 为 1 或 2；RN 为 H 或 Me；R1 可任选为一个或多个卤代或甲基；R2a 和 R2b 独立选自以下组：(i) F；(ii) H；(iii) Me；和 (iv) CH2OH；R2c 和 R2d（如存在）独立选自以下组：(i) F；(ii) H；(iii) Me；和 (iv) CH2OH；R3a 和 R3b 独立选自 H 和 Me；R4a 选自 OH、-NHH 或 Me：(R3a和R3b独立选自H和Me；R4a选自OH、-NH2、-C(═O)NH2和-CH2OH；R4b不是H就是Me；R5不是H就是Me；A是(i)任选取代的苯基；(ii)任选取代的萘基；或(iii)任选取代的C5-12杂芳基。
• Pyrazole compounds and methods of making and using same
  申请人：Lundbeck La Jolla Research Center, Inc.

  公开号：US10385057B2

  公开（公告）日：2019-08-20

  Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.

  本文提供了吡唑化合物和包含所述化合物的药物组合物。所述化合物和组合物可用作 MAGL 和/或 FAAH 的调节剂。此外，所述化合物和组合物还可用于治疗疼痛等疾病。
• SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS
  申请人：Novartis AG

  公开号：EP2956464B1

  公开（公告）日：2018-03-28